RecruitingPhase 1NCT07787208

A Study of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid Tumors

A Phase 1, Open-label, Dose Escalation Study to Investigate the Safety and Tolerability of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid Tumors

Sponsor

Ono Pharmaceutical Co., Ltd.

Enrollment

80 participants

Start Date

Jun 19, 2026

Study Type

INTERVENTIONAL

Conditions

Solid Tumors

Summary

This study is to evaluate the tolerability and safety of ONO-7429 in participants with unresectable advanced or recurrent solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ONO-7429 for people with solid tumors. The study is currently recruiting participants at 10 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGONO-7429

Specified dose on specified days

Locations(10)

National Cancer Center Hospital East

Kashiwa, Chiba, Japan

Gunma University Hospital

Maebashi, Gunma, Japan

Niigata Cancer Center Hospital

Niigata, Niigata, Japan

Kansai Medical University Hospital

Hirakata, Osaka, Japan

Osaka International Cancer Institute

Osaka, Osaka, Japan

Kindai University Hospital

Sakai, Osaka, Japan

Saitama Medical University International Medical Center

Hidaka, Saitama, Japan

Shizuoka Cancer Center

Sunto-gun, Shizuoka, Japan

National Cancer Center Hospital

Chuo-ku, Tokyo, Japan

The Cancer Institute Hospital of JFCR

Koto-ku, Tokyo, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07787208

Related Trials

A Study of DS3610a in Participants With Advanced Solid Tumor

NCT071591262 locations

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

NCT0749268057 locations

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873780 locations

REC-7735 in Participants With Solid Tumors

NCT07819136

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

NCT033661161 location